Reaction
Epidermodysplasia Verruciformis reporting signals
As of the last recalculation, Epidermodysplasia Verruciformis appears in 165 FAERS reports alongside 5 co-occurring drug terms. The strongest observed disproportionality signal is SIROLIMUS (PRR 165.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Sirolimus | 16 | 165.8 | 166.0 |
| Tacrolimus Ointment 0.1% | 80 | 156.4 | 156.5 |
| Tacrolimus Extended-Release Capsules | 80 | 155.9 | 156.0 |
| Mycophenilic Acid | 19 | 130.6 | 130.7 |
| Efavirenz | 7 | 82.7 | 82.7 |